Relfydess: The Anti-Wrinkle Treatment That Lasts Up to Six Months

Every conventional botulinum toxin product arrives as a lyophilised powder. Before it reaches a patient, it must be reconstituted with saline. The dilution ratio, the technique, the timing, the storage conditions after mixing, all of these affect the final product. Two practitioners using the same powder product in different clinics on different days are not necessarily administering an identical solution. Most patients never think about this. I think about it constantly.

Relfydess changes it entirely. And that, for a practitioner who thinks the way I do, is genuinely significant.

What PEARL technology actually means

PEARL stands for Precipitation-free Extraction and Activity-preserving Refined Liquid. It is the manufacturing process that produces a complex-free, ready-to-use liquid formulation. Relfydess arrives as a liquid. No reconstitution. No dilution ratio to calculate. No variability introduced by mixing technique or storage time after preparation.

PEARL Technology vs Conventional Formulations

Feature	PEARL Technology (Relfydess)	Conventional Botulinum Toxins
Format	Ready-to-use liquid	Lyophilised powder
Reconstitution Needed	No	Yes
Mixing Variability	Eliminated	Possible
Dilution Errors	Eliminated	Possible
Storage Variability After Mixing	Eliminated	Possible
Complexing Proteins	Removed	Present
Consistency Between Vials	Highly standardised	Dependent on preparation technique
Focus of Innovation	Precision and consistency	Traditional reconstitution workflow

The complexing proteins removed in this process deserve a mention. Conventional botulinum toxin products carry proteins that accompany the active molecule but contribute nothing to the treatment effect. Their presence, however, may increase immunogenicity, the likelihood of the body developing antibodies that could reduce treatment efficacy over repeated sessions.

Removing them is not just a manufacturing convenience. It is a clinically relevant decision.

What this means for a practitioner trained to value precision: every dose is the same. Every vial is consistent. The variables that exist with reconstituted products simply do not exist here. For patients, that translates to more predictable, reproducible outcomes from one appointment to the next. For me, it removes a source of variability I have always been uncomfortable leaving uncontrolled.

What the READY trials actually found

The clinical programme for Relfydess, known as the READY trials, is one of the largest Phase 3 programmes conducted for a botulinum toxin neuromodulator, involving over 1,900 participants across multiple studies evaluating frown lines and crow's feet. I want to walk through the numbers carefully because they are meaningfully different from what we see in existing products.

The READY-1 trial, published in the Aesthetic Surgery Journal in November 2024, was a double-blind, randomised, placebo-controlled Phase 3 study in 297 participants evaluating glabellar lines. The headline findings: 82.9% of participants achieved a two-grade or greater improvement at one month, compared to 0% in the placebo group. 96.3% had none or mild frown lines at maximum contraction at peak effect. 39% saw measurable improvement from day one. 75% had not returned to baseline wrinkle severity at 169 days, approximately five and a half months.

The day one figure is the one I find most clinically interesting. Most existing neuromodulators don't demonstrate that. The duration figure matters too. Three to four months is the standard expectation for conventional products. Seventy-five percent of participants still below baseline at nearly six months is a meaningful difference.

Clinical Trial Results Table

Study	Participants	Key Findings
READY-1 Phase 3	297	82.9% achieved ≥2-grade improvement at 1 month
READY-1 Phase 3	297	96.3% had none or mild frown lines at peak effect
READY-1 Phase 3	297	39% saw improvement from Day 1
READY-1 Phase 3	297	75% had not returned to baseline at 169 days
READY-1 Patient Outcomes	297	83% reported natural-looking results
READY-1 Patient Outcomes	297	75% felt confident making facial expressions
READY-4 Long-Term Safety	900+	Consistent efficacy and satisfaction across repeated treatments

The patient experience data is, if anything, more compelling than the efficacy numbers. A patient-reported outcomes paper from the READY-1 study, published in the Aesthetic Surgery Journal in July 2025, found that more than 83% of participants reported natural-looking results and more than 75% felt confident making expressions. Patient satisfaction remained consistent across the full six-month follow-up period.

That last detail is the one I keep returning to. Confidence in making natural facial expressions is not a cosmetic vanity metric. It is a measure of whether a treatment has done what good aesthetic medicine is supposed to do: help someone feel like themselves. When that confidence holds for six months, that is a result worth noting.

The Phase 3 READY-4 long-term safety trial, involving over 900 participants across multiple treatment cycles over twelve months, confirmed that efficacy and patient satisfaction were maintained across repeated treatments, with a safety profile consistent with the earlier studies. The safety data is reassuring. The consistency data is what I find most relevant.

What this means in practice

I want to be precise about what Relfydess changes and what it does not, because precision is exactly the point.

What changes: reconstitution variability is eliminated. Dosing consistency is improved. Onset is demonstrably rapid, with results measurable from day one in a significant proportion of patients. Duration of effect in trials extends up to six months for many patients, longer than the typical three to four months cited for conventional products. What does not change: the anatomy of your face. The need for individual assessment before every treatment. The importance of adjusted dosing based on your specific muscle strength, asymmetries, and treatment history. The fact that brow position, facial balance, and expression preservation all depend on the practitioner's anatomical knowledge and clinical judgement, not the product alone.#

Relfydess vs Conventional Botulinum Toxin

Feature	Relfydess	Conventional Products
Formulation	Ready-to-use liquid	Lyophilised powder
Reconstitution Required	No	Yes
Dilution Variability	Eliminated	Possible
Onset of Effect	Measurable from Day 1 in many patients	Usually several days
Duration	Up to 6 months in many patients	Typically 3–4 months
Complexing Proteins	Removed	Present
Dosing Consistency	Highly standardised	Dependent on mixing technique
Storage After Preparation	No post-mixing variability	Variable after reconstitution

Technology improves consistency. Skill determines outcomes. A ready-to-use formulation reduces one source of variability in the treatment process. It does not replace the consultation, the mapping, the measurement, or the two-week review that distinguishes careful, evidence-based anti-wrinkle treatment from a rushed appointment with identical dosing for every patient.

What Relfydess treats and what it does not

Botulinum toxin treats dynamic wrinkles: lines caused by repeated muscle movement. Frown lines between the brows, crow's feet around the eyes, forehead lines, and certain lower face concerns including downturned mouth corners and chin dimpling all respond well to precise, conservative neuromodulator treatment.

It does not treat volume loss, for which dermal fillers are the appropriate tool. It does not address skin laxity, for which PDO threads or HIFU address the structural causes. It does not improve skin quality, for which polynucleotides, Profhilo, or PRP are more appropriate. And it does not significantly affect static wrinkles, lines present at rest without muscle movement, which require a different approach.

What Botulinum Toxin Treats

Treats Well	Does Not Treat
Frown lines	Volume loss
Crow’s feet	Skin laxity
Forehead lines	Skin quality concerns
Downturned mouth corners	Static wrinkles at rest
Chin dimpling	Significant tissue sagging

Understanding which concern requires which treatment is the foundation of a genuinely useful consultation. It is why I discuss the full picture at every appointment rather than simply treating what a patient arrives asking about.

A note on UK regulation

Botulinum toxin is a prescription-only medicine in the UK. As the MHRA has confirmed, it must be sold and supplied only in accordance with a prescription from an appropriate prescriber. This applies to Relfydess as it does to every botulinum toxin product.

The JCCP has published guidance stating that patients should receive a face-to-face consultation with a prescribing professional before any botulinum toxin procedure. That is the standard at Juvenology. Always has been. The regulatory landscape is simply catching up with what good clinical practice already required.

Frequently asked questions

Is Relfydess available at Juvenology?

Yes. It is part of the treatment options offered at Juvenology Clinic in Maidstone. Which specific product is used for your treatment is discussed as part of your full consultation, where individual needs, anatomy, and treatment history are all assessed before any decision is made.

How long does Relfydess last?

Clinical trials demonstrate results lasting up to six months in many patients, with 75% of READY-1 participants not returning to baseline at 169 days. Individual response varies and duration is influenced by factors including muscle strength, metabolism, and treatment history.

Does the ready-to-use formulation make a difference to patients?

It improves consistency between appointments. Because there is no reconstitution step, the product each patient receives is identical from one visit to the next, reducing a source of variability that exists with conventional powder-based products.

What is PEARL technology?

PEARL stands for Precipitation-free Extraction and Activity-preserving Refined Liquid. It is the manufacturing process that produces a complex-free, ready-to-use liquid formulation, removing the complexing proteins present in conventional botulinum toxin products that do not contribute to treatment effect but may affect immunogenicity over time.

How is this different from other botulinum toxins?

Products such as Botox and Azzalure arrive as lyophilised powder and require reconstitution before use. Relfydess is the first product in this class to arrive as a ready-to-use liquid, removing the reconstitution variable and providing volumetric dosing precision. The clinical evidence also demonstrates a notably rapid onset and duration of up to six months.

If you are considering anti-wrinkle treatment, or want to discuss whether Relfydess is appropriate for your anatomy and treatment history, book a consultation at Juvenology.

We see patients from across Kent including Maidstone, Tonbridge, Sevenoaks, Kings Hill, West Malling, Medway, and Chatham.

About Juvenology Clinic

Juvenology Clinic is an aesthetics and longevity-focused clinic based in Maidstone, Kent. It was founded by Nurse Marina, a clinician with 25 years of nursing experience, including six years in cardiac care at KIMS Hospital. The clinic integrates regenerative aesthetic medicine with longevity science, combining clinical precision from critical care with preventive and aesthetic healthcare approaches.

Founder & Clinical Background

Nurse Marina brings a background in acute and cardiac nursing alongside advanced training in longevity and hormonal health. Her qualifications include:

• Executive MSc in Longevity from the Geneva College of Longevity Science

• Healthy Longevity Clinician Programme at the National University of Singapore

• NMC Registered nurse

• Memberships and affiliations including JCCP Verified, BACN Member, ACE Group Registered, Royal College of Nursing, and recognition by the Professional Standards Authority

Clinical Approach

The clinic’s approach blends:

• Regenerative aesthetic medicine

• Evidence-based preventive health strategies

• Longevity science principles

• Anatomically precise, medically informed treatment planning

Clinical references

Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines — Shridharani SM et al. Aesthetic Surgery Journal, November 2024 academic.oup.com/asj/article/44/12/1330/7697878 pubmed.ncbi.nlm.nih.gov/38913088

Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial — Gold MH et al. Aesthetic Surgery Journal, July 2025 doi.org/10.1093/asj/sjaf063 pubmed.ncbi.nlm.nih.gov/40242960

Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation — PMC Full Text ncbi.nlm.nih.gov/pmc/articles/PMC12260373

READY-1 Phase 3 Trial — PMC Full Text pmc.ncbi.nlm.nih.gov/articles/PMC11566037

ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma's

RelabotulinumtoxinA — Galderma Press Release, October 2024 galderma.com/news/asds-2024-new-phase-iii-ready-4-data-demonstrate-long-term-safety-and-efficacy-galdermas